CT-101
Sickle Cell Disease
Pre-clinicalActive - Lead candidate nominated
Key Facts
Indication
Sickle Cell Disease
Phase
Pre-clinical
Status
Active - Lead candidate nominated
Company
About Cetya Therapeutics
Founded in 2012 and based in Fort Collins, Colorado, Cetya Therapeutics is developing isoform-selective histone deacetylase inhibitors (HDACi) derived from largazole, a natural product. The company has nominated its lead candidate, CT-101, for the treatment of sickle cell disease, a significant unmet medical need. Cetya has strengthened its leadership with key board appointments and secured intellectual property through a process patent for its novel synthetic route, positioning itself to advance its pipeline.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Decitabine combination | Novo Nordisk | Phase 2 |
| CTX001 | Vertex Pharmaceuticals | Phase 3 |
| DISC-3405 | Disc Medicine | Phase 1 |
| Mitapivat | Agios Pharmaceuticals | Phase 2/3 |
| FTX-6058 | Fulcrum Therapeutics | Phase 1b |
| BIVV003 | Sangamo Therapeutics | Phase 1/2 |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |